BioAtla logo
BioAtla
BCAB | NASDAQ
Chart Builder DCF Calculator
$1.74
+$0.42 (+31.82%)
At close: Aug 28, 2026, 4:00 PM ET

BioAtla Company Profile

Company profile explained

Company Profile

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

Key Executives

Name Position
Jay Short Co-Founder, Chief Executive Officer & Chairman
Cathy Chang Senior Vice President of Research & Development
Christian Vasquez CFO, CAO, Controller & Corporate Secretary
Eric L. Sievers Chief Medical Officer
Gerhard Frey Senior Vice President of Technology Development
Lisa Pelton Accounting Manager
Monica Sullivan Senior Vice President of Intellectual Property & Contracts
Sheri Lydick Chief Commercial Officer
Susie Melody Senior Vice President of Human Resources

Latest SEC Filings

Date Type Title
Sep 29, 2026 8-K Current Report
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Aug 28, 2026 8-K Current Report
Aug 13, 2026 10-Q Quarterly Report
Jul 16, 2026 8-K Current Report
Jun 05, 2026 4 Filing
Jun 05, 2026 4 Filing
Jun 05, 2026 4 Filing
View All SEC Filings ➞
BioAtla
BioAtla logo
Country United States
IPO Date Dec 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Jay Short

Contact Details

11085 Torreyana Road San Diego, California 92121 United States

Stock Details

Ticker Symbol BCAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001826892
CUSIP Number 09077B203
ISIN Number US09077B2034
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.